Exhibit 99.2
TENDER AND SUPPORT AGREEMENT
THIS TENDER AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of August 2, 2021, by and between Sanofi, a French société anonyme (“Parent”), and the undersigned stockholders (collectively, the “Stockholder”) of Translate Bio, Inc., a Delaware corporation (the “Company”).
WITNESSETH:
WHEREAS, the Company, Parent and Vector Merger Sub, Inc., a Delaware corporation (“Purchaser”) have entered into an Agreement and Plan of Merger of even date herewith (the “Merger Agreement”);
WHEREAS, pursuant to the Merger Agreement, among other things, (i) Purchaser will commence a cash tender offer (as it may be amended from time to time as permitted under the Merger Agreement, the “Offer”) to acquire all of the outstanding shares of common stock of the Company (the “Company Common Stock”) and, following the completion of the Offer, (ii) Purchaser will be merged with and into the Company, the separate corporate existence of Purchaser will thereupon cease and the Company will continue as the surviving corporation and a wholly owned subsidiary of Parent (the “Merger”);
WHEREAS, as of the date hereof, the Stockholder or its affiliates (which term shall be understood, with respect to an individual, to include the immediate family members of such individual) is the beneficial owner (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended from time to time (the “Exchange Act”)) of that number of Shares set forth on the signature page of this Agreement; and
WHEREAS, as a condition and inducement to the willingness of the Company and Parent to enter into the Merger Agreement, the Stockholder (in the Stockholder’s capacity as such) has agreed to enter into this Agreement.
NOW, THEREFORE, intending to be legally bound, the parties hereto agree as follows:
1. Certain Definitions. All capitalized terms that are used but not defined herein shall have the respective meanings ascribed to them in the Merger Agreement. For all purposes of and under this Agreement, the following terms shall have the following respective meanings:
(a) “Expiration Date” shall mean the earliest to occur of (i) such date and time as the Merger Agreement shall have been validly terminated pursuant to Article VIII thereof, (ii) the Effective Time, (iii) the date of any material modification, material waiver or material amendment to any provision of the Merger Agreement or (iv) a Company Adverse Change Recommendation.
(b) “Shares” shall mean (i) all shares of capital stock of the Company (including the Company Common Stock) beneficially owned by the Stockholder or its affiliates as of the date hereof and (ii) all additional shares of capital stock of the Company (including the Company Common Stock) which the Stockholder or its affiliates acquires beneficial ownership of during the period from the date of this Agreement through the Expiration Date (including by way of exercise of any convertible or derivative security, stock dividend or distribution, split-up, recapitalization, combination, exchange of shares and the like), including shares of Company Common Stock acquired through the exercise of Company Options.